Market Overview

Benzinga's Top #PreMarket Gainers

Related EXEL
The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines
Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA
Institutional Top Ideas: Great Point Partners (Seeking Alpha)
Related PGNX
Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study
42 Biggest Movers From Friday

Exelixis (NASDAQ: EXEL) shares gained 12.78% to $3.75 in pre-market trading after the company reported that coBRIM has met primary endpoint in phase 3 trial.

Progenics Pharmaceuticals (NASDAQ: PGNX) shares surged 11.08% to $4.71 in pre-market trading. Salix Pharmaceuticals (NASDAQ: SLXP) and Progenics reported that the FDA Office of Drug Evaluation III has approved Salix request for the FDA approval of RELISTOR sNDA.

URS (NYSE: URS) shares jumped 7.92% to $56.14 in pre-market trading after Aecom Technology (NYSE: ACM) announced its plans to buy URS for $4 billion in cash and stock.

Mylan (NASDAQ: MYL) shares gained 3.59% to $52.00 in pre-market trading after the company announced its plans to acquire Abbott's (NYSE: ABT) non-U.S. developed markets specialty and branded generics business in a $5.3 billion all-stock transaction.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers


Related Articles (ABT + ACM)

View Comments and Join the Discussion!